吉西他滨联合多西紫杉醇新辅助化疗方案在局部晚期肺癌的疗效观察

目的：观察吉西他滨联合多西紫杉醇用于Ⅲ期非小细胞肺癌（NSCLC）新辅助化疗的效果及耐受性。方法：67例Ⅲ期NSCLC手术患者，术前接受新辅助化疗。其中，GT组32例，接受gemcitabine＋docetaxel方案，与同期接受长春瑞滨（NVB）＋DDP方案（NP组）35例作比较。结果：GT组，CR1例，PR14例，总有效率46．88％；NP组，CR2侧，PR16例，总有效率51．43％，两组有效率无显著性差异（P〉0．05）；化疗后肿瘤分期下降两组分别为：GT组43．75％（14／32），NP组45．71％（16／35），两组比较无显著性差异（P〉0．05）。结论：吉西他滨联合多西紫杉醇用于NSCLC术前新辅助化疗效果肯定，该方案可作为NSCLC术前新辅助化疗的可选择方案。

The Observation of Therapy Effect on Gemcitabine Plus Docetaxei as Preoperative Neoadjuvant Chemotherapy for Locally Advance no-small Cell Lung Cancer

Objective：To evaluate efficacy and toxicity of gemcitabine plus docetaxel regimen in preoperative adjuvant chemotherapy in patients with Ⅲ stages NSCLC. Methods：In all of the 67 patients with stage HI NSCLC,32cases received gemcitabine ＋ docetaxel （GT） ,while the other 35 cases received NVB ＋ DDP（NP） regimen. The therapeutic efficacy and toxicity of GT regimen were observed and with NP regimen. Results：The overall response rate was 46. 88% for GT group with 1 complete response（CR） and 14 partial response（PR） ,and 51.43% in the NP group with 2 CR and 16 PR（P 〉0. 05）. There were 14 （43.75%） ,down after preoperative chemotherapy in GT group, and 16（45. 71% ）in NP group（ P 〉 0. 05 ）. There was no significant difference between the two groups （P 〉 0. 05 ）. Conclusions： GT regimen was a highly active regimen of the neoadjuvant chemotherapy for NSCLC, and it could be used as a regimen for the preoperative neoadjuvant chemotherapy of NSCLC.